Table 2.
Characteristics of 21 Patients with SMN after Neuroblastoma
| Pt # |
Sex | Race | Neuroblastoma | Second Malignancy | Outcome (yrs after SM diagnosis) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age at Dx (yrs) |
Primary Site Group |
INSS Stage |
Year of Diagnosis |
Chemotherapy | Radiation Therapy |
Age at Diagnosis (years) |
Latency (years) |
Histologic diagnosis | Site | SMN within RT field? |
||||
| 1 | F | W | 0.1 | Adrenal | 4 | 1963 | Cy, V | None | 44.3 | 44.2 | Squamous cell carcinoma | Uterine cervix | No | Alive (3.7) |
| 2 | M | W | 0.2 | Abdomen-Nonadrenal | 4 | 1971 | V,Cy | Abdomen 33 Gy Pelvis 15.45 Gy |
27.1 | 26.9 | Hodgkin lymphoma | Inguinal Lymph Node | Yes | Alive (13.7) |
| 3 | M | AA | 1.7 | Adrenal | 4 | 1971 | V,Cy,D | Abdomen 29 Gy Mediastinum 28 Gy Skull 39 Gy |
10.8 | 9.0 | Malignant peripheral nerve sheath tumor | Frontal Lobe | Yes | Expired (0.8) |
| 4 | M | W | 0.02 | Thoracic | 4 | 1972 | V,Cy,D Imm | Abdomen 26.75 Gy Mediastinum 12.5 Gy |
29.7 | 29.7 | Adenocarcinoma | Colon | Yes | Expired (3.1) |
| 5 | F | AA | 1.2 | Cervical | 2B | 1973 | Cy | Lateral neck 35 Gy | 19.7 | 18.5 | Papillary carcinoma | Thyroid | Yes | Alive (19.6) |
| 6 | F | W | 4.0 | Pelvic | 3 | 1973 | V,Cy,D Imm | Abdomen/Pelvis 25 Gy | 9.5 | 5.4 | Acute myelomonocytic leukemia | N/A | Expired (0.9) | |
| 7 | M | W | 0.9 | Abdomen-Nonadrenal | 1 | 1976 | None | Paraspinal 23.25 Gy | 6.7 | 5.8 | Basal cell carcinoma | Back | Yes | Alive (29.4) |
| 8 | F | W | 1.1 | Adrenal | 1 | 1977 | None | Abdomen 24 Gy | 14.2 | 13.1 | Rhabdoid tumor | Posterior mediastinum | No | Expired (0.6) |
| 9 | M | W | 0.7 | Adrenal | 2B | 1977 | Cy,D Imm | None | 25.2 | 24.5 | Squamous cell carcinoma | Tongue | No | Alive (9.4) |
| 10 | F | W | 0.02 | Thoracic | 1 | 1980 | Cy,D | None | 10.7 | 10.7 | Mucoepidermoid carcinoma | Submandibular gland | No | Alive (21.4) |
| 11 | F | AA | 1.1 | Abdomen-Nonadrenal | 4 | 1981 | Cy,D,P,T | None | 26.2 | 25.0 | Clear cell carcinoma | Abdomen –unclear organ of origin | No | Expired (1.2) |
| 12 | M | W | 0.5 | Cervical | 2B | 1982 | Cy,D,P,T | None | 16.3 | 15.8 | Osteosarcoma | Maxilla | No | Alive (12.7) |
| 13 | F | W | 3.1 | Adrenal | 4 | 1983 | Cy,D,P,T | None | 27.3 | 24.2 | Renal cell carcinoma | Left kidney | No | Alive (3.8) |
| 14 | F | W | 8.7 | Adrenal | 4 | 1984 | Cy,D,P,T | None | 10.0 | 1.3 | Acute myelomonocytic leukemia | N/A | Expired (1.0) | |
| 15 | F | AA | 1.5 | Adrenal | 4 | 1989 | Cy,D,P,I,Car,E | None | 7.0 | 5.6 | Rhabdomyosarcoma (embryonal) | Thigh | No | Expired (0.4) |
| 16 | M | W | 0.9 | Pelvic | 2B | 1993 | Cy,D | None | 12.0 | 11.1 | Basal cell carcinoma | Chest | No | Alive (8.0) |
| 17 | F | W | 5.1 | Nasal Cavity | 2A | 1993 | V,Cy,D,I,E,Dac | Nasal cavity 30.5 Gy | 7.4 | 2.3 | Myelodysplastic syndrome [t(11;16)] | N/A | Expired (2.1) | |
| 18 | M | AA | 3.6 | Adrenal | 4 | 1997 | V,Cy,D,I,E,Top | None | 8.5 | 4.9 | Acute monocytic leukemia [t(9;11)(p22;q23)] | N/A | Expired (0.7) | |
| 19 | F | W | 3.3 | Adrenal | 2B | 2000 | Cy, D, E, Car | None | 12.3 | 9.0 | Gastrointestinal stromal tumor (GIST) | Stomach | No | Alive (0.9) |
| 20 | F | W | 6.1 | Cervical | 2B | 2003 | Cy,D,E,Car | Neck 30.6 Gy | 10.8 | 4.7 | Ewing sarcoma | Lumbar spine | No | Alive (4.0) |
| 21 | M | B | 2.2 | Abdomen-Nonadrenal | 2B - >4* | 2005 | Cy,D,P,E,Ir,Top,Car,M | Abdomen 23.4 Gy | 5.2 | 3.1 | Rhabdomyosarcoma (spindle cell) | Abdomen | Yes | Expired (3.5) |
Abbreviations: Dx, diagnosis; M, male; F, female; W, white; AA, African-American; V, vincristine; Cy, cyclophosphamide; D, doxorubicin; P, cisplatin; T, teniposide; I, ifosfamide; E, etoposide; Car, carboplatin; Dac, dactinomycin; Ir, irinotecan; M, melphalan; Imm, immunotherapy with BCG vaccine
*
developed widely metastatic disease after initial surgery for localized disease